ArticleFrontiers in cardiovascular medicine2025
Global trends of cardiovascular disease burden attributable to high body mass index from 1990 to 2021 and projections to 2035.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gut microbiota-derived metabolites in cardiovascular disease: mechanisms, disease-specific roles, and translational opportunities.Frontiers in cardiovascular medicine · 2026Review
- Ischemic Heart Disease and the Epidemiologic Transition: Progress without Reduction in Global Burden.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular disease (CVD) remains the leading cause of mortality and disability globally, with high body mass index (HBMI) playing a pivotal role in its worldwide burden. Gaining a clear understanding and forecasting the effect of HBMI on CVD is crucial for developing effective health policies and interventions. Methods: We used data from the 2021 Global Burden of Disease study to analyze the CVD burden attributable to HBMI. An age-period-cohort (APC) analysis was conducted to investigate trends in CVD-related mortality attributable to HBMI, whereas the Bayesian Age-Period-Cohort (BAPC) model projected the number of deaths and mortality up to 2035. Results: The study revealed a significant increase in CVD deaths and disability-adjusted life years (DALYs) due to HBMI globally, despite slightly decreased age-standardized rates (ASR) for HBMI-related CVD. The ASR of deaths and DALYs decreased from 1990 to 2021 in the high and high-middle Socio-Demographic Index (SDI) regions while increasing in the lower SDI regions. A pinpoint analysis revealed the most significant decline in HBMI-related CVD mortality from 2003 to 2010. The BAPC model projected an increase in global HBMI-related CVD deaths to 2,369,451 by 2035. The ASR of deaths is projected to increase to 37.53 per 100,000, with an increase for females and a decrease for males. Conclusion: This study emphasizes global trends in HBMI-related CVD burden and the importance of targeting HBMI as a modifiable risk factor. It provides crucial information for public health strategies aimed at reducing CVD mortality. Further research is warranted, especially with an aging global population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.